STEVE ASELAGE - 12 Jun 2024 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Alane P. Barnes, by power of attorney
Issuer symbol
BCRX
Transactions as of
12 Jun 2024
Net transactions value
$0
Form type
4
Filing time
14 Jun 2024, 16:20:58 UTC
Previous filing
29 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Award $0 +6,820 +11% $0.000000 70,159 12 Jun 2024 Direct F1
holding BCRX Common Stock 2,500 12 Jun 2024 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Automatic Stock Option Grant Award $0 +49,933 $0.000000 49,933 12 Jun 2024 Common Stock 49,933 $6.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2 Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.